Abstract:The PI3K–AKT pathway is hyperactivated in many human cancers, and several drugs to inhibit this pathway, including the PI3K/mTOR dual inhibitor NVP-BEZ235, are currently being tested in various preclinical and clinical trials. It has been shown that pharmacologic inhibition of the PI3K–AKT pathway results in feedback activation of other oncogenic signaling pathways, which likely will limit the clinical utilization of these inhibitors in cancer treatment. However, the underlying mechanisms of such feedback regulation remain incompletely understood. The PI3K–AKT pathway is a validated therapeutic target in renal cell carcinoma (RCC). Here, we show that FoxO transcription factors serve to promote AKT phosphorylation at Ser473 in response to NVPBEZ235 treatment in renal cancer cells. Inactivation of FoxO attenuated NVP-BEZ235–induced AKT Ser473 phosphorylation and rendered renal cancer cells more susceptible to NVP-BEZ235–mediated cell growth suppression in vitro and tumor shrinkage in vivo. Mechanistically, we showed that FoxOs upregulated the expression of Rictor, an essential component of MTOR complex 2, in response to NVP-BEZ235 treatment and revealed that Rictor is a key downstream target of FoxOs in NVP-BEZ235–mediated feedback regulation. Finally, we show that FoxOs similarly modulate the feedback response on AKT Ser473 phosphorylation and renal tumor growth by other phosphoinositide 3-kinase (PI3K) or AKT inhibitor treatment. Together, our study reveals a novel mechanism of PI3K–AKT inhibition-mediated feedback regulation and may identify FoxO as a novel biomarker to stratify patients with RCC for PI3K or AKT inhibitor treatment, or a novel therapeutic target to synergize with PI3K–AKT inhibition in RCC treatment. Cancer Res; 74(6); 1682–93. 2014 AACR.

Inhibition of Rb Phosphorylation Leads to Mtorc2-Mediated Activation of Akt

Understanding Retinoblastoma Post-Translational Regulation for the Design of Targeted Cancer Therapies

Supplementary Methods and Figures Legends from FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

Molecular and Cellular Pathobiology FoxO Transcription Factors Promote AKT Ser 473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI 3 K – AKT Pathway

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors

Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1

E2F1/CKS2/PTEN signaling axis regulates malignant phenotypes in pediatric retinoblastoma

Interplay between lysine methylation and Cdk phosphorylation in growth control by the retinoblastoma protein

Depleted hexokinase1 and lack of AMPKα activation favor OXPHOS-dependent energetics in retinoblastoma tumors

PRMT4-Mediated Arginine Methylation Negatively Regulates Retinoblastoma Tumor Suppressor Protein and Promotes E2F-1 Dissociation

Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb

SUMOylation of Rb Enhances Its Binding with CDK2 and Phosphorylation at Early G1 Phase

Dual Phosphorylation of Sin1 at T86 and T398 Negatively Regulates Mtorc2 Complex Integrity and Activity

PtdIns(3,4,5)P3-Dependent Activation of the Mtorc2 Kinase Complex

Targeting Rb Mutant Cancers by Inactivating TSC2

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

Sin1 Phosphorylation Impairs Mtorc2 Complex Integrity and Inhibits Downstream Akt Signalling to Suppress Tumorigenesis

Inhibition of 4EBP Phosphorylation Mediates the Cytotoxic Effect of Mechanistic Target of Rapamycin Kinase Inhibitors in Aggressive B-cell Lymphomas

CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors